Mortality and morbidity after combined heart and liver transplantation in the failing Fontan: An updated dual center retrospective study
Sumeet S. Vaikunth, Juan Ortega–Legaspi, Desireé Conrad, Sharon Chen, Tami Daugherty, Christiane Haeffele, Jeffrey J. Teuteberg, Rhondalynn Mclean, John W. MacArthur, Y. Joseph Woo, Katsuhide Maeda, Michael Ma, Teimour Nasirov, Marrouf Hoteit, Moira Hilscher, Joyce Wald, Tal Mandelbaum, Kim M. Olthoff, Peter L. Abt, Pavan Atluri, Marisa Cevasco, Constantine Mavroudis, Stephanie Fuller, George K. Lui, Yuli Y. Kim
Abstract
INTRODUCTION: As the adult Fontan population with Fontan associated liver disease continues to increase, more patients are being referred for transplantation, including combined heart and liver transplantation. METHODS: We report updated mortality and morbidity outcomes after combined heart and liver transplant in a retrospective cohort series of 40 patients (age 14 to 49 years) with Fontan circulation across two centers from 2006-2022. RESULTS: The 30-day, 1-year, 5-year and 10-year survival rate was 90%, 80%, 73% and 73% respectively. Sixty percent of patients met a composite comorbidity of needing either post-transplant mechanical circulatory support, renal replacement therapy or tracheostomy. Cardiopulmonary bypass time > 283 min (4.7 h) and meeting the composite comorbidity were associated with mortality by Kaplan Meier analysis. CONCLUSION: Further study to mitigate early mortality and the above comorbidities as well as the high risk of bleeding and vasoplegia in this patient population is warranted.